These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27739124)

  • 1. Aducanumab reduces Aβ plaques in Alzheimer's disease.
    Vaillancourt DE
    Mov Disord; 2016 Nov; 31(11):1631. PubMed ID: 27739124
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.
    Kastanenka KV; Bussiere T; Shakerdge N; Qian F; Weinreb PH; Rhodes K; Bacskai BJ
    J Neurosci; 2016 Dec; 36(50):12549-12558. PubMed ID: 27810931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
    Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I
    CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aducanumab: The first targeted Alzheimer's therapy.
    Yang P; Sun F
    Drug Discov Ther; 2021; 15(3):166-168. PubMed ID: 34234067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source.
    Patel KR
    Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718
    [No Abstract]   [Full Text] [Related]  

  • 6. Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease.
    Gamage KK; Kumar S
    J Neurosci; 2017 Apr; 37(17):4430-4432. PubMed ID: 28446659
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
    Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
    J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
    Rabinovici GD
    N Engl J Med; 2021 Aug; 385(9):771-774. PubMed ID: 34320284
    [No Abstract]   [Full Text] [Related]  

  • 9. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.
    Arndt JW; Qian F; Smith BA; Quan C; Kilambi KP; Bush MW; Walz T; Pepinsky RB; Bussière T; Hamann S; Cameron TO; Weinreb PH
    Sci Rep; 2018 Apr; 8(1):6412. PubMed ID: 29686315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aducanumab-Hope or Disappointment for Alzheimer's Disease.
    Wojtunik-Kulesza K; Rudkowska M; Orzeł-Sajdłowska A
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data.
    Høilund-Carlsen PF; Alavi A
    J Alzheimers Dis; 2021; 84(4):1457-1460. PubMed ID: 34657891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aducanumab: a new phase in therapeutic development for Alzheimer's disease?
    Lalli G; Schott JM; Hardy J; De Strooper B
    EMBO Mol Med; 2021 Aug; 13(8):e14781. PubMed ID: 34338436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aducanumab: look before leaping.
    Perlmutter JS
    Nat Med; 2021 Sep; 27(9):1499. PubMed ID: 34413517
    [No Abstract]   [Full Text] [Related]  

  • 14. Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer's disease.
    Kandadi Muralidharan K; Tong X; Kowalski KG; Rajagovindan R; Lin L; Budd Haberlain S; Nestorov I
    CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):7-19. PubMed ID: 34697913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solanezumab and the amyloid hypothesis for Alzheimer's disease.
    Le Couteur DG; Hunter S; Brayne C
    BMJ; 2016 Dec; 355():i6771. PubMed ID: 28034844
    [No Abstract]   [Full Text] [Related]  

  • 16. Microglia contributes to plaque growth by cell death due to uptake of amyloid β in the brain of Alzheimer's disease mouse model.
    Baik SH; Kang S; Son SM; Mook-Jung I
    Glia; 2016 Dec; 64(12):2274-2290. PubMed ID: 27658617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why aducanumab is important.
    Cummings J
    Nat Med; 2021 Sep; 27(9):1498. PubMed ID: 34413516
    [No Abstract]   [Full Text] [Related]  

  • 18. Commentary: Aducanumab-Related ARIA: Paean or Lament?
    Wassef HR; Colletti PM
    Clin Nucl Med; 2022 Aug; 47(8):707-709. PubMed ID: 35543641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Aducanumab and Alzheimer's disease: a critical reflection.].
    Vanacore N; Blasimme A; Canevelli M
    Recenti Prog Med; 2021; 112(7):495-498. PubMed ID: 34263875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.
    Bouter Y; Lopez Noguerola JS; Tucholla P; Crespi GA; Parker MW; Wiltfang J; Miles LA; Bayer TA
    Acta Neuropathol; 2015 Nov; 130(5):713-29. PubMed ID: 26467270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.